Cover Image
市場調查報告書

全球溶小體儲積症市場

Global Lysosomal Storage Diseases Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310019
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
全球溶小體儲積症市場 Global Lysosomal Storage Diseases Market 2014-2018
出版日期: 2014年07月30日 內容資訊: 英文 64 Pages
簡介

全球溶小體儲積症市場,預計從2013年到2018年,以10.01%的CAGR(年複合成長率)擴大。

本報告提供全球溶小體儲積症市場現狀與今後的預測、藥物類別與各地區的趨勢、市場的發展因素與課題、主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 溶小體儲積症治療的第一個認證藥
  • 波特的五力分析

第8章 市場區隔:各類藥物

  • ERT
  • SRT
  • Cystine-Depletors

第9章 地區區分

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Genzyme
    • Shire
    • BioMarin
    • Actelion

第18章 其他

  • 其他有潛力的供應商

第19章 主要供應商分析

  • Actelion
    • 產業概要
    • 主要資訊
    • SWOT分析
  • BioMarin
  • Genzyme
  • Shire

第20章 相關報告

圖表清單

目錄
Product Code: IRTNTR3860

About Lysosomal Storage Diseases

The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular transport between lysosome and other cellular compartments. These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate stored, cell types affected by this storage, and resulting organ involvement. Due to the high variability of these components, the clinical manifestations of even a single disease vary from person to person. These symptoms also vary between members of the same family with identical mutations. The age of onset also varies for lysosomal storage diseases depending on the rate of substrate accumulation. Lysosomal storage diseases are classified on the basis of the substrate being accumulated or on the type of molecular defect associated with the disease. Neuronal ceroid-lipofuscinoses vary from classical lysosomal storage diseases where the component that gets accumulated is mitochondrial ATP synthase subunit C or sphingolipid activator proteins A and D.

TechNavio's analysts forecast the Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Lysosomal Storage Diseases market for the period 2014-2018. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases, which include:

  • Gaucher disease
  • Fabry disease
  • Mucopolysaccharidosis
  • Pompe disease
  • Cystinosis
  • NPC

TechNavio's report, the Global Lysosomal Storage Diseases Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Lysosomal Storage Diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Actelion Pharmaceuticals Ltd.
  • BioMarin Pharmaceutical Inc.
  • Genzyme Corp.
  • Shire plc

Other Prominent Vendors

  • Mylan
  • Pfizer
  • Protalix
  • Raptor
  • Recordati
  • Sigma-Tau

Key Market Driver

  • Special Provisions for Orphan Drugs

For a full, detailed list, view our report.

Key Market Challenge

  • Increase in Generic Erosion

For a full, detailed list, view our report.

Key Market Trend

  • Fierce Market Competition
  • Increasing Use of Statins.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Portfolio

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. First Approved Drugs for Treatment of Lysosomal Storage Diseases
  • 07.4. Five Forces Analysis

08. Market Segmentation by Drug Class

  • 08.1.1. ERTs
  • 08.1.2. SRT
  • 08.1.3. Cystine-Depletors

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
    • 17.2.1. Genzyme
    • 17.2.2. Shire
    • 17.2.3. BioMarin
    • 17.2.4. Actelion

18. Others

  • 18.1. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Actelion
    • 19.1.1. Business Overview
    • 19.1.2. Key Information
    • 19.1.3. SWOT Analysis
  • 19.2. BioMarin
    • 19.2.1. Business Overview
    • 19.2.2. Key Information
    • 19.2.3. SWOT Analysis
  • 19.3. Genzyme
    • 19.3.1. Business Overview
    • 19.3.2. Key Information
    • 19.3.3. SWOT Analysis
  • 19.5. Shire
    • 19.5.1. Business Overview
    • 19.5.2. Key Information
    • 19.5.3. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Lysosomal Storage Diseases
  • Exhibit 3: Global Lysosomal Storage Diseases Market 2013-2018 (US$ billion)
  • Exhibit 4: Global Lysosomal Storage Diseases Market Segmentation by Drug Class
  • Exhibit 5: Global Lysosomal Storage Diseases Market Segmentation by Drug Class 2013
  • Exhibit 6: Global Lysosomal Storage Diseases Market by Geographical Segmentation 2013
  • Exhibit 7: Market Revenue for Major Drugs 2013
  • Exhibit 8: Percentage Revenue Share of LSD Drugs of Genzyme 2013
  • Exhibit 9: Geography-wise Revenue of Genzyme Corp.'s LSD Products in 2013 (US$ million)
  • Exhibit 10: Geography-wise Revenue of Genzyme Corp's LSD Products in 2013
  • Exhibit 11: Geography-wise Revenue of Naglazyme in 2013 (US$ million)
Back to Top